Universal Beteiligungs und Servicegesellschaft mbH Takes Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 97,123 shares of the biotechnology company’s stock, valued at approximately $62,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.12% of CytomX Therapeutics as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the stock. Miller Financial Services LLC lifted its stake in shares of CytomX Therapeutics by 104.0% in the 1st quarter. Miller Financial Services LLC now owns 51,000 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 26,000 shares during the period. Assenagon Asset Management S.A. lifted its stake in shares of CytomX Therapeutics by 18.6% in the 1st quarter. Assenagon Asset Management S.A. now owns 711,454 shares of the biotechnology company’s stock valued at $452,000 after purchasing an additional 111,604 shares during the period. Formidable Asset Management LLC raised its stake in CytomX Therapeutics by 55.5% during the 4th quarter. Formidable Asset Management LLC now owns 382,529 shares of the biotechnology company’s stock worth $394,000 after buying an additional 136,528 shares during the period. Velan Capital Investment Management LP acquired a new stake in CytomX Therapeutics during the 4th quarter worth $36,000. Finally, Tidal Investments LLC raised its stake in CytomX Therapeutics by 55.5% during the 4th quarter. Tidal Investments LLC now owns 382,529 shares of the biotechnology company’s stock worth $394,000 after buying an additional 136,528 shares during the period. Institutional investors and hedge funds own 67.77% of the company’s stock.

Analyst Ratings Changes

CTMX has been the topic of several research analyst reports. Wedbush reaffirmed an “outperform” rating and set a $6.00 price objective (up previously from $5.00) on shares of CytomX Therapeutics in a research note on Monday, May 12th. Wall Street Zen raised CytomX Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, May 13th. Piper Sandler raised their price objective on CytomX Therapeutics from $2.50 to $5.00 and gave the stock an “overweight” rating in a research note on Thursday, May 15th. HC Wainwright raised CytomX Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective on the stock in a research note on Thursday, May 15th. Finally, Oppenheimer initiated coverage on CytomX Therapeutics in a research note on Thursday, July 31st. They set an “outperform” rating and a $7.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $5.75.

CytomX Therapeutics Price Performance

CTMX opened at $2.37 on Wednesday. The business’s 50-day moving average price is $2.42 and its two-hundred day moving average price is $1.43. CytomX Therapeutics, Inc. has a 1 year low of $0.40 and a 1 year high of $3.10. The company has a market capitalization of $191.07 million, a price-to-earnings ratio of 4.94 and a beta of 2.13.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.09. CytomX Therapeutics had a negative return on equity of 553.71% and a net margin of 28.22%. The firm had revenue of $50.92 million for the quarter, compared to the consensus estimate of $35.42 million. During the same quarter last year, the business posted $0.17 EPS. Sell-side analysts anticipate that CytomX Therapeutics, Inc. will post -0.05 earnings per share for the current fiscal year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.